

Membrane Proteomics has emerged as a Tool to Study Carbapenem Resistance in *Acinetobacter baumannii*

Vishvanath Tiwari*

Department of Biochemistry, Central University of Rajasthan, Ajmer, Rajasthan, 305801, India

Acinetobacter baumannii is one of the most important opportunistic pathogens described by Infectious Disease Society of America [1]. Due to its lethality, it is grouped into ESKAPE pathogens (group of hospital-acquired infection causing pathogens). Reports on the ESKAPE pathogen showed that more people now die in US due to the ESKAPE pathogen infections than of HIV/AIDS and tuberculosis combined [2,3]. *Acinetobacter baumannii* has emerged as a threat to soldiers, wounded during military operations in Iraq and Afghanistan [4,5] as well as isolated from natural resources [6]. It causes pneumonia, urinary tract infections and respiratory infections. *Acinetobacter baumannii* has ability to survive on artificial surfaces and utilize ethanol as a carbon source [7], resist desiccation, grow at various temperatures and pH conditions [8] this make it a notorious pathogen. Prevalence of *Acinetobacter baumannii* in clinical setup increases with time [9]. Carbapenems are most commonly prescribed β -lactam against *A. baumannii* [10]. Emergence of resistance against carbapenem is a significant health problem & associated with high morbidity & mortality [11] which makes it one of the major concerns [9,12,13].

Proteomics emerged as a tool to study the differential proteome under diverse conditions. Cytoplasmic proteins have often been used in proteomic studies. Membrane plays an important role in the survival of bacteria as it act as a barrier between bacterium and external environment inside the host. With the development of proteomics, a considerable progress has been made in the recent years in the field of membrane proteomics [14,15]. Prof. Vila group, Spain, first reported the membrane proteome of carbapenem resistance strain of *Acinetobacter baumannii* [16]. Similarly, Siroy et al. [17] also performed the global comparison of the membrane sub-proteomes of multidrug-resistant *Acinetobacter baumannii* strain and a reference strain. Membrane proteomics has been also employed for the study of the resistance mechanism for other drugs like colistin used against *A. baumannii* [18]. Using membrane proteomics approach, Soares et al. [19] showed that *Acinetobacter baumannii* displays a robust and versatile metabolism. With the help of outer membrane proteomics, Kwon et al. [20] studied the secretion of outer membrane vesicles (OMVs) from a clinical *A. baumannii* isolate and analysed the comprehensive proteome of *A. baumannii*-derived OMVs. Not only that high-end isoelectric point (pH 6-11) membrane proteome analysis of *Acinetobacter radioresistens* S-13 reveals that envelope stress responses can be induced by aromatic compounds [21]. Biofilm formation is one of the main causes for the persistence of *Acinetobacter baumannii* on the surface of host epithelial cells. Cabral et al. [22] performed proteomics of *Acinetobacter* cultured in three different conditions (exponential, late stationary phase and biofilms stage) and they also checked the effects of biofilm inhibitory compound (salicylate) on the biofilm formation. This multiple-approach strategy showed a unique lifestyle of *A. baumannii* involved in biofilms formation. Yun et al. [23] performed quantitative proteomic analysis of cell wall and plasma membrane fractions from multidrug-resistant *Acinetobacter baumannii* and reported that carbapenem induces the expression of resistance-nodulation-cell division transporters,

protein kinases and suppress outer membrane proteins expression. Lee et al. [24] explain the mechanism of hetero-resistance induced by imipenem in the multidrug resistance *Acinetobacter baumannii*. Rajeswari et al [25] showed the importance of outer membrane in the carbapenem resistance using outer membrane proteomics of carbapenem resistance strain of *Acinetobacter baumannii*. Tiwari et al. [13] identified the importance of the metabolism in the carbapenem resistance of *Acinetobacter* using inner membrane proteomics. Role of iron in the survival of ATCC strain and carbapenem resistance strain of *Acinetobacter baumannii* in human host has also been studied using membrane proteomics [26,27].

These updates show that membrane proteomics has now emerged as an important tool to understand the mechanism of carbapenem resistance in *Acinetobacter baumannii*. Membrane proteomics also helps to understand the role of different environments/conditions in the survival of *Acinetobacter baumannii* and its adaptation as a notorious pathogen.

References

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, et al. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1-12.
2. Kleven RM, Edwards JR, Tenover FC, McDonald LC, Horan T, et al. (2006) Changes in the epidemiology of methicillin-resistant *Staphylococcus aureus* in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 42: 389-391.
3. Boucher HW, Corey GR (2008) Epidemiology of methicillin-resistant *Staphylococcus aureus*. Clin Infect Dis 46 Suppl 5: S344-349.
4. Davis KA, Moran KA, McAllister CK, Gray PJ (2005) Multidrug-resistant *Acinetobacter* extremity infections in soldiers. Emerg Infect Dis 11: 1218-1224.
5. Camp C, Tatum OL (2010) A Review of *Acinetobacter baumannii* as a highly successful pathogen in times of war. Lab Med 41: 649-657.
6. Kempf M, Rolain JM, Diatta G, Azza S, Samb B, et al. (2012) Carbapenem resistance and *Acinetobacter baumannii* in Senegal: the paradigm of a common phenomenon in natural reservoirs. PLoS One 7: e39495.
7. Navon-Venezia S, Ben-Ami R, Carmeli Y (2005) Update on *Pseudomonas aeruginosa* and *Acinetobacter baumannii* infections in the healthcare setting. Curr Opin Infect Dis 18: 306-313.
8. Bergogne-Bérézin E, Towner KJ (1996) *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9: 148-165.

*Corresponding author: Vishvanath Tiwari, Department of Biochemistry, Central University of Rajasthan, Ajmer, Rajasthan, 305801, India, Tel: + 91-1463-238652; Fax: + 91-1463-238722; E-mail: vishvanath7@yahoo.co.in

Received February 25, 2014; Accepted March 01, 2014; Published March 04, 2014

Citation: Tiwari V (2014) Membrane Proteomics has emerged as a Tool to Study Carbapenem Resistance in *Acinetobacter baumannii*. J Proteomics Bioinform 7: e26. doi:10.4172/0974-276X.10000e26

Copyright: © 2014 Tiwari V. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

9. Tiwari V, Kapil A, Moganty RR (2012) Carbapenem-hydrolyzing oxacillinase in high resistant strains of *Acinetobacter baumannii* isolated from India. Microb Pathog 53: 81-86.
10. Hawkey PM, Jones AM (2009) The changing epidemiology of resistance. J Antimicrob Chemother 64 Suppl 1: i3-10.
11. Sengstock DM, Thyagarajan R, Apalara J, Mira A, Chopra T, et al. (2010) Multidrug-resistant *Acinetobacter baumannii*: an emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis 50: 1611-1616.
12. Tiwari V, Nagpal I, Subbarao N, Moganty RR (2012) *In-silico* modeling of a novel OXA-51 from β -lactam-resistant *Acinetobacter baumannii* and its interaction with various antibiotics. J Mol Model 18: 3351-3361.
13. Tiwari V, Vashist J, Kapil A, Moganty RR (2012) Comparative proteomics of inner membrane fraction from carbapenem-resistant *Acinetobacter baumannii* with a reference strain. PLoS One 7: e39451.
14. Tan S, Tan HT, Chung MC (2008) Membrane proteins and membrane proteomics. Proteomics 8: 3924-3932.
15. Santoni V, Molloy M, Rabilloud T (2000) Membrane proteins and proteomics: un amour impossible? Electrophoresis 21: 1054-1070.
16. Martí S, Sánchez-Céspedes J, Oliveira E, Bellido D, Giralt E, et al. (2006) Proteomic analysis of a fraction enriched in cell envelope proteins of *Acinetobacter baumannii*. Proteomics 6 Suppl 1: S82-87.
17. Siroy A, Cosette P, Seyer D, Lemaître-Guillier C, Vallenet D, et al. (2006) Global comparison of the membrane subproteomes between a multidrug-resistant *Acinetobacter baumannii* strain and a reference strain. J Proteome Res 5: 3385-3398.
18. Fernández-Reyes M, Rodríguez-Falcón M, Chiva C, Pachón J, Andreu D, et al. (2009) The cost of resistance to colistin in *Acinetobacter baumannii*: a proteomic perspective. Proteomics 9: 1632-1645.
19. Soares NC, Cabral MP, Parreira JR, Gayoso C, Barba MJ, et al. (2009) 2-DE analysis indicates that *Acinetobacter baumannii* displays a robust and versatile metabolism. Proteome Sci 7: 37.
20. Kwon SO, Gho YS, Lee JC, Kim SI (2009) Proteome analysis of outer membrane vesicles from a clinical *Acinetobacter baumannii* isolate. FEMS Microbiol Lett 297: 150-156.
21. Mazzoli R, Fattori P, Lamberti C, Giuffrida MG, Zapponi M, et al. (2011) High isoelectric point sub-proteome analysis of *Acinetobacter radioresistens* S13 reveals envelope stress responses induced by aromatic compounds. Mol Biosyst 7: 598-607.
22. Cabral MP, Soares NC, Aranda J, Parreira JR, Rumbo C, et al. (2011) Proteomic and functional analyses reveal a unique lifestyle for *Acinetobacter baumannii* biofilms and a key role for histidine metabolism. J Proteome Res 10: 3399-3417.
23. Yun SH, Choi CW, Kwon SO, Park GW, Cho K, et al. (2011) Quantitative proteomic analysis of cell wall and plasma membrane fractions from multidrug-resistant *Acinetobacter baumannii*. J Proteome Res 10: 459-469.
24. Lee H, Chenb C, Wangb S, Sud L, Chenb S, et al (2011) Imipenem heteroresistance induced by imipenem in multidrug-resistant *Acinetobacter baumannii*: mechanism and clinical implications. Int J Antimicrob Agents 37: 302-308.
25. Vashist J, Tiwari V, Kapil A, Rajeswari MR (2010) Quantitative profiling and identification of outer membrane proteins of beta-lactam resistant strain of *Acinetobacter baumannii*. J Proteome Res 9: 1121-1128.
26. Nwugo CC, Gaddy JA, Zimbler DL, Actis LA (2011) Deciphering the iron response in *Acinetobacter baumannii*: A proteomics approach. J Proteomics 74: 44-58.
27. Tiwari V, Moganty RR (2013) Effect of iron availability on the survival of carbapenem-resistant *Acinetobacter baumannii*: a proteomic approach. J Proteomics Bioinform 6: 125-131.